SCHEMBL3980741

SCHEMBL3980741

Nc1ncnc2snc(-c3ccc4ccc(-c5ccccc5)nc4c3F)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.47
IGF1R P08069 14/20 0.47
INSR P06213 3/20 0.47
MAP4K4 O95819 3/20 0.44
DAPK3 O43293 1/20 0.44
PRKD3 O94806 1/20 0.44
ABL1 P00519 1/20 0.44
NTRK1 P04629 1/20 0.44
LCK P06239 1/20 0.44
CSF1R P07333 1/20 0.44
RET P07949 1/20 0.44
MET P08581 1/20 0.44
PDGFRB P09619 1/20 0.44
FGFR1 P11362 1/20 0.44
PDGFRA P16234 1/20 0.44
PRKACA P17612 1/20 0.44
FLT1 P17948 1/20 0.44
LTK P29376 1/20 0.44
MAP2K2 P36507 1/20 0.44
MAPK8 P45983 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3980028 0.87 KDR (0.43) KDRIGF1RINSRMAP4K4DAPK3
SCHEMBL3978833 0.84 KDR (0.62) KDRIGF1RINSRMAP4K4DAPK3
SCHEMBL3980068 0.83 KDR (0.42) KDRIGF1RMAP4K4DAPK3PRKD3
SCHEMBL3982004 0.80 KDR (0.52) KDRMAP4K4DAPK3PRKD3ABL1
SCHEMBL3985507 0.77 KDR (0.55) KDRIGF1RINSRMAP4K4DAPK3
SCHEMBL3986247 0.72 KDR (0.48) KDRIGF1RINSRMAP4K4DAPK3
SCHEMBL3978986 0.71 KDR (0.50) KDRMAP4K4DAPK3PRKD3ABL1
SCHEMBL400054 0.71 SRC (0.47) KDRIGF1RINSRABL1CYP1A2
SCHEMBL3980829 0.70 KDR (0.62) KDRINSRMAP4K4DAPK3PRKD3
SCHEMBL4247951 0.70 PADI1 (0.40) IGF1RINSRCDK7CDK5DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032512-A1 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC., 2007-02-08 US claimed
US-7566721-B2 Substituted thienol[2,3-d]pyrimidines as kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-07-28 US disclosed
US-20070032512-A1 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC., 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032512-A1 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors IGF1R, BRCA1, MAP2K6 KDR 2130/4885IGF1R 1/4885INSR 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.